Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | NPY4R | P50391 | 7/20 | 0.39 |
| ▸ | NPY1R | P25929 | 5/20 | 0.39 |
| ▸ | NPY2R | P49146 | 4/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.39 |
| ▸ | OTC | P00480 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 3/20 | 0.38 |
| ▸ | NOS1 | P29475 | 3/20 | 0.38 |
| ▸ | NOS2 | P35228 | 3/20 | 0.38 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.37 |
| ▸ | RRM1 | P23921 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10292018 | 1.00 | DPP7 (0.43) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL8214683 | 1.00 | DPP7 (0.43) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL16421890 | 0.95 | DPP7 (0.46) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL10190380 | 0.95 | DPP7 (0.46) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL13320657 | 0.95 | DPP7 (0.46) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL13434929 | 0.89 | ANPEP (0.37) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL12278048 | 0.89 | ANPEP (0.37) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL8125131 | 0.89 | ANPEP (0.37) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL18542868 | 0.87 | DPP7 (0.44) | DPP7OTCGNAI3GNAO1GNAI1 | |
| SCHEMBL19368710 | 0.87 | DPP7 (0.44) | DPP7OTCGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0564588-B1 | HEXAPEPTIDE ANAPHYLATOXIN-RECEPTOR LIGANDS | ABBOTT LAB (US) | 1997-02-12 | — | — | EP | claimed |
| US-11786547-B2 | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | SYNEDGEN, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230181623-A1 | COMPOSITIONS AND METHODS OF USE FOR WOUND HEALING | SYNEDGEN, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2023086557-A1 | NUCLEOSIDES FOR THE TREATMENT OF DNA VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-2968080-B1 | ORAL FORMULATION OF POLYGLUCOSAMINE DERIVATIVES IN COMBINATION WITH A NON-FERMENTABLE SUGAR | SYNEDGEN INC (US) | 2023-05-10 | — | — | EP | disclosed |
| WO-2022174179-A9 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20230021050-A1 | COMPOSITIONS AND METHODS OF THEIR USE | SYNEDGEN, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| WO-2021221656-A1 | COMPOSITIONS AND METHODS OF USE THEREOF | SYNEDGEN, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021159044-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20120295355-A1 | NUCLEIC ACID DELIVERY USING MODIFIED CHITOSANS | BAKER SHENDA (US) | 2012-11-22 | — | — | US | disclosed |
| US-8119780-B2 | Chitosan-derivative compounds and methods of controlling microbial populations | SYNEDGEN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| WO-2011127144-A1 | METHODS AND COMPOSITIONS FOR TREATING WOUNDS UTILIZING CHITOSAN COMPOUNDS | SYNEDGEN INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011028968-A1 | ORAL CARE METHODS AND COMPOSITIONS UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | SYNEDGEN, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028967-A1 | METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | SYNEDGEN INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2010056927-A1 | CHITOSAN DERIVATIVES ALONE OR IN COMBINATION FOR THE TREATMENT OF MDR MICROBIAL INFECTIONS | SYNEDGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056896-A1 | CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH | SYNEDGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100056474-A1 | Methods and Compositions for the Prevention of and Treatment of Infections Utilizing Chitosan-Derivative Compounds | UNITED STATES GOVERNMENT | 2010-03-04 | — | — | US | disclosed |
| WO-2010021930-A1 | PREVENTION AND TREATMENT OF MRSA INFECTIONS WITH CHITOSAN-DERIVATIVES | SYNEDGEN, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20070281904-A1 | Chitosan-derivative compounds and methods of controlling microbial populations | UNITED STATES GOVERNMENT | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181623-A1 | COMPOSITIONS AND METHODS OF USE FOR WOUND HEALING | PARG, ARGLU1, AREG | DPP7 599/4885NPY4R 3554/4885NPY1R 3373/4885 |
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | ENTPD1, NME2, NME1 | DPP7 2457/4885NPY4R 3768/4885NPY1R 4259/4885 |
| US-20100056474-A1 | Methods and Compositions for the Prevention of and Treatment of Infections Utilizing Chitosan-Derivative Compounds | NRDC, ARG1, CHIA | DPP7 864/4885NPY4R 3234/4885NPY1R 1855/4885 |
| US-20230021050-A1 | COMPOSITIONS AND METHODS OF THEIR USE | ARG1, ARG2, FUT6 | DPP7 1233/4885NPY4R 1463/4885NPY1R 1560/4885 |
| US-20070281904-A1 | Chitosan-derivative compounds and methods of controlling microbial populations | ARG1, NRDC, CHIA | DPP7 305/4885NPY4R 593/4885NPY1R 840/4885 |
| US-11786547-B2 | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | CHIT1, ALG1, CSGALNACT1 | DPP7 1094/4885NPY4R 3948/4885NPY1R 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.